SUBSCRIBE Blog with us: BLOGbiotech

GEN News Highlights

• Email
• Print
• Share
• More GEN News Highlights

Nov 9 2009, 10:54 AM EST

Boehringer Ingelheim Pledges $22.5M to Fund Another Four Years of Partnership with Evotec

GEN News Highlights

Evotec and Boehringer Ingelheim extended their drug discovery and preclinical development collaboration for another four years. The companies have also added oncology to the range of diseases covered by their partnership.

During the term of the extension Boehringer Ingelheim will provide Evotec with research funding of about €15 million, or almost $22.5 million, over that pledged as part of the initial agreement.

Boehringer Ingelheim and Evotec initiated their collaboration for the discovery and preclinical development of small molecule drugs in 2004. The partnership has now been extended three times and covers central nervous system disorders, inflammation, cardiometabolic disorders, respiratory diseases, and oncology. 

Evotec has to date received seven milestone payments from Boehringer Ingelheim. The most recent €2.5 million (about $3.75 million) fee was received in October and related to the selection of a candidate for preclinical development studies in a cardiometabolic program.

Milestone payments and potential future sales royalties linked to anticancer molecules identified under the broadened relationship between the firms will also be due. Boehringer Ingelheim retains full ownership and responsibility for worldwide clinical development, manufacture, and commercialization of all compounds identified through the collaboration.

 

♦♦♦
Related News
Evotec Earns Roughly $3.75M as Seventh Milestone Fee from Boehringer Ingelheim (Oct. 22, 2009)
Evotec Cuts Workforce with New Focus on Forging Discovery Partnership (Mar. 27, 2009)
Ono Taps Evotec for Discovery Work (Mar. 27, 2008)
Evotec Boosts Drug Discovery Business through Deal with Combinature (June 13, 2007)
Evotec, Boehringer Ingelheim, and IMP Form Alzheimer’s Disease Target Discovery Collaboration (Mar. 19, 2007)

• Email
• Print
• Share
• More GEN News Highlights

Comment on this News:

Name:
Title:
Comment:
	HELP US FIGHT SPAMMING ROBOTS by answering the following simple question. It will verify you as a legitimate user wishing to post a comment. Thank you for your cooperation.

CAREER CENTER

WEBINARS

PODCASTS

MOST POPULAR